Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07187206 · ClinicalTrials.gov registry record · Phase 3
Safety and Efficacy of FETO in CDH Phase III
A Phase 3 study of Pulmonary Hypertension and Congenital Diaphragmatic Hernia, sponsored by Children's Hospital Medical Center, Cincinnati.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 75
- Enrollment target
- 1
- Study location
NCT07187206 is a Phase 3 study of Pulmonary Hypertension and Congenital Diaphragmatic Hernia that is actively recruiting participants, run by Children's Hospital Medical Center, Cincinnati. The registered enrollment target is 75 participants, below the 613-participant average among 72 other Pulmonary Hypertension trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07187206, a Phase 3 study of Pulmonary Hypertension and Congenital Diaphragmatic Hernia, is actively recruiting participants, sponsored by Children's Hospital Medical Center, Cincinnati.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 75 participants
- Enrollment target
- 1
- Study location
Study Summary
Tracheal occlusion IDE approved by FDA for congenital diaphragmatic hernia fetuses and standard of care control group
Conditions Studied
Interventions
- DEVICE FETO, Fetal Endoluminal Tracheal Occlusion
Study Locations (1)
Ohio
- Cincinnati Children's Hospital Medical Center (CCHMC) - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2025-09-30 |
| Est. Completion | 2033-03-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07187206
The ClinicalTrials.gov registry entry for NCT07187206 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 613-participant average among 72 other Pulmonary Hypertension trials with a reported enrollment target (88% lower). The listed sponsor is Children's Hospital Medical Center, Cincinnati, which has 571 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Pulmonary Hypertension appearing as the primary indexed condition, and to 1 intervention - of which FETO, Fetal Endoluminal Tracheal Occlusion is the first listed.
NCT07187206 reports 1 study location spanning 1 distinct geographic area - top geographies include Ohio.
Frequently Asked Questions
What is clinical trial NCT07187206 about?
NCT07187206 is a clinical study titled "Safety and Efficacy of FETO in CDH Phase III". Tracheal occlusion IDE approved by FDA for congenital diaphragmatic hernia fetuses and standard of care control group
What is the current status of trial NCT07187206?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 75 participants. The study started on 2025-09-30. Estimated completion is 2033-03-01.
What conditions does trial NCT07187206 study?
This clinical trial studies the following conditions: Pulmonary Hypertension, Congenital Diaphragmatic Hernia, Pulmonary Hypoplasia.
What interventions are being tested in trial NCT07187206?
The interventions under investigation include: FETO, Fetal Endoluminal Tracheal Occlusion (DEVICE).
Who is sponsoring clinical trial NCT07187206?
This trial is sponsored by Children's Hospital Medical Center, Cincinnati, which has 571 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07187206 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pulmonary Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF
RECRUITING · Phase 3
-
Efficacy and Safety Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)
RECRUITING · Phase 3
-
Clinical Investigation Into Inhaled Treprostinil Sodium in Patients With Severe Pulmonary Arterial Hypertension (PAH)
COMPLETED · Phase 3
-
Efficacy and Safety of Oral Bosentan in Pulmonary Arterial Hypertension Class II
COMPLETED · Phase 3
-
Efficacy and Safety of Oral UT-15C Tablets to Treat Pulmonary Arterial Hypertension
COMPLETED · Phase 3
-
A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients With CTEPH.
COMPLETED · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.